Digital Twins Tentatively Finding Traction in the Pharmaceutical Industry

Subscribe To Read This Insight

By Tancred Taylor | 3Q 2020 | IN-5904


Applications in the Pharmaceutical Industry


While asset and process twins have seen significant interest and adoption in the manufacturing space, the pharmaceutical industry is one where uptake has been much slower. The technologies are, however, increasingly seeing development by digital twin technology suppliers; as accuracy and capabilities mature, digital twins will drive reams of new applications in the pharmaceutical space.

Early research projects for digital twins in the pharmaceutical industry have looked at creating models of patients’ bodies. Certara’s Virtual Twin solution (2018) models individual patients based on physical and genetic attributes to help predict the impact of certain drugs and dosages on a case-by-case basis. Dassault’s Living Heart (2014) and Living Brain (2019) projects create digital models of the named organs for testing and studying drugs or medical interventions. Siemens Healthineers, Hewlett Packard, GE, and Philips are among other companies working on digital models of organs for similar purposes.

These early research-stage applications have more recently bee…

You must be a subscriber to view this ABI Insight.
To find out more about subscribing contact a representative about purchasing options.